Dr Bruce M Topol, MD | |
36 Bay St, Manchester, NH 03104-3003 | |
(603) 622-0900 | |
(603) 622-5955 |
Full Name | Dr Bruce M Topol |
---|---|
Gender | Male |
Speciality | Plastic Surgery |
Location | 36 Bay St, Manchester, New Hampshire |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1518959832 | NPI | - | NPPES |
30200841 | Medicaid | NH |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208200000X | Plastic Surgery | 10889 (New Hampshire) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Bruce M Topol, MD 36 Bay St, Manchester, NH 03104-3003 Ph: (603) 622-0900 | Dr Bruce M Topol, MD 36 Bay St, Manchester, NH 03104-3003 Ph: (603) 622-0900 |
News Archive
Jeffery Dusek, PhD, Director of Research at University Hospitals (UH) Connor Integrative Health Network and Associate Professor in the Department of Family Medicine and Community Health at Case Western Reserve University, and colleagues were recently awarded a 3-year, $2+ million grant from the National Center of Complementary and Integrative Health, part of the National Institutes of Health.
A study issued today by HealthGrades, Inc., the leading independent healthcare ratings organization, finds that Good Samaritan Hospital is among the Top 5% in the Nation for Treatment of Stroke and Top 10% in the Nation for Joint Replacement. The nation's nearly 5,000 nonfederal hospitals were all included in the sweeping study, which examined mortality rates and complication rates from government data from 2006, 2007 and 2008.
Introducing competing "biosimilar" versions of complex biologic drugs used to treat illnesses such as cancer and rheumatoid arthritis could cut spending on biologics in the United States by $44 billion over the next decade, according to new analysis from the RAND Corporation.
Threshold Pharmaceuticals, Inc., today announced two preclinical presentations on its clinical stage hypoxia-activated prodrug, TH-302, at the American Association for Cancer Research Translational Cancer Medicine Meeting, being held July 11 to 14, 2010, in San Francisco, CA. The preclinical presentations describe new findings regarding the efficacy of TH-302 when combined with multi-kinase inhibitors that inhibit VEGF signaling, as well as the efficacy of TH-302 in combination with gemcitabine in models of pancreatic cancer.
› Verified 9 days ago
Dr. Emese Kalnoki-kis, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 185 Queen City Ave, Manchester, NH 03101 Phone: 603-314-6450 Fax: 603-314-6459 | |
Robert S Feins, M.D. Plastic Surgery Medicare: Not Enrolled in Medicare Practice Location: 144 Tarrytown Rd, Manchester, NH 03103 Phone: 603-647-4430 Fax: 603-647-4877 | |
Peter Thomas Pacik, M.D. Plastic Surgery Medicare: Not Enrolled in Medicare Practice Location: 57 Bay St, Manchester, NH 03104 Phone: 603-669-0290 Fax: 603-669-4040 |